Russell Investments Group Ltd. Cuts Stock Position in bluebird bio, Inc. (NASDAQ:BLUE)

Russell Investments Group Ltd. lessened its stake in shares of bluebird bio, Inc. (NASDAQ:BLUEFree Report) by 14.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 84,601 shares of the biotechnology company’s stock after selling 13,977 shares during the period. Russell Investments Group Ltd. owned approximately 0.08% of bluebird bio worth $117,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Citigroup Inc. raised its position in shares of bluebird bio by 5.8% in the 3rd quarter. Citigroup Inc. now owns 557,969 shares of the biotechnology company’s stock worth $1,696,000 after purchasing an additional 30,532 shares during the last quarter. Deutsche Bank AG lifted its stake in shares of bluebird bio by 80.8% in the third quarter. Deutsche Bank AG now owns 692,881 shares of the biotechnology company’s stock worth $2,106,000 after buying an additional 309,690 shares in the last quarter. Bleichroeder LP purchased a new stake in shares of bluebird bio during the third quarter valued at approximately $2,736,000. Aigen Investment Management LP bought a new stake in shares of bluebird bio during the third quarter valued at approximately $34,000. Finally, Vanguard Group Inc. increased its position in shares of bluebird bio by 0.8% during the third quarter. Vanguard Group Inc. now owns 5,617,460 shares of the biotechnology company’s stock valued at $17,077,000 after acquiring an additional 46,216 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Stock Performance

Shares of bluebird bio stock opened at $0.97 on Friday. The stock has a market cap of $105.97 million, a P/E ratio of -1.31 and a beta of 0.82. The stock’s fifty day moving average is $1.12 and its 200 day moving average is $1.73. bluebird bio, Inc. has a one year low of $0.85 and a one year high of $5.53.

Analysts Set New Price Targets

Several analysts have commented on the company. Wells Fargo & Company cut their target price on bluebird bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Wednesday, March 27th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $6.00 price objective on shares of bluebird bio in a report on Wednesday, March 27th. Wedbush lowered their target price on shares of bluebird bio from $1.72 to $1.68 and set a “neutral” rating on the stock in a research note on Tuesday, March 19th. HSBC reduced their price target on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating for the company in a research note on Tuesday, March 5th. Finally, StockNews.com upgraded shares of bluebird bio to a “sell” rating in a report on Thursday, March 28th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. According to MarketBeat, bluebird bio has an average rating of “Hold” and a consensus target price of $5.74.

Check Out Our Latest Stock Report on bluebird bio

bluebird bio Profile

(Free Report)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

Recommended Stories

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.